Clinical Trial

An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia

Study acronym: AKM Lab-01
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 29, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study was to assess the safety and efficacy of AKM Lab-01 in subjects with hypercholesterolemia. This study will be conducted as a randomized, double-blind, placebo-controlled trial, eligible hypercholesterolemic participants were administered daily oral doses of either AKM Lab-01 or a placebo. Baseline clinical parameters, blood samples, and stool specimens were collected before and after the intervention for comparative analysis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-08; most recent amendment 2026-06-25.
Status change: Not Yet Recruiting → Recruiting 2025-12-23
Trial Details
NCT Number NCT06974266
Lead Sponsor Moon (Guangzhou) Biotechnology Co., Ltd.
Conditions Hypercholesterolaemia
Enrollment 60 participants
Start Date 2025-06-25
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-29